Samsung Biologics invests in new plant to expand Bio Campus

Samsung Biologics, the leading end-to-end CDMO, is set to start building a new plant based in North Korea, to expand its biomanufacturing capabilties. 

The building of the 96,000 m² plant is set to commence this year, with a view to be operational come 2025. It will be the first facility to run under their Bio Campus initiative. The plant will have a capacity of 180,000 litres, bringing Samsung Biologic’s global biomanufacturing capacity to 784,000 litres. 

“Given the continuing increase in the demand for outsourced manufacturing of biopharmaceuticals, we are proactively making this investment in alignment with our growth strategy to further strengthen our standing as a leading CDMO,” stated John Rim, President and CEO of Samsung Biologics. “The new facility will enable us to provide our customers with even greater innovation and services that will increase speed to market and flexibility.”

Samsung Biologics are expecting the plant to increase their operational output and efficiency by building on their already acquired expertise, and the technology they have honed through the years in their previous plants. This plant will take this experience one step further with increased use of digitalised technologies and the inclusion of important sustainability-led features. 

The second Bio Campus, on which the plant will be based, will also be home to further operational plants and an innovation hub. The campus will cover 360,000 m² of land and will bear the fruits of a KRW 7.5 trillion investment. 
The company’s existing plants are nearly fully functional, with the latest, plant 4, due to be fully operational by the middle of this year. 

To further streamline their operations and support their expansion into the US, Samsung Biologics are opening an office in New Jersey, USA in April. 

“Our increased US presence will allow us to provide support for clients with even greater agility and engage the broader biotech industry more than ever,” commented Rim.